-
Electronic (PDF)
-
Site License
-
Enterprisewide
Ambrx, Inc. - Product Pipeline Review - H2 2011
Global Markets Direct, November 2011, Pages: 40
Ambrx, Inc. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Ambrx, Inc. - Product Pipeline Review - H2 2011” provides data on the Ambrx, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ambrx, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ambrx, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Ambrx, Inc. - Brief Ambrx, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ambrx, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ambrx, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ambrx, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Ambrx, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ambrx, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ambrx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ambrx, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ambrx, Inc. and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Ambrx, Inc.; Ambrx, Inc. - Key Therapeutics; Ambrx, Inc. - Pipeline Overview and Promising Molecules; Ambrx, Inc. - News; Ambrx, Inc. - Latest Updates; Ambrx, Inc. - Pipeline; Ambrx, Inc. - Discontinued/Dormant Projects
List of Tables
List of Figures
Ambrx, Inc. Snapshot
Ambrx, Inc. Overview
Key Information
Key Facts
Ambrx, Inc. – Research and Development Overview
Key Therapeutic Areas
Ambrx, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Ambrx, Inc. – Pipeline Products Glance
Ambrx, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Ambrx, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ambrx, Inc. – Drug Profiles
ARX-201
Product Description
Mechanism of Action
R&D Progress
ARX201
Product Description
Mechanism of Action
R&D Progress
Ambrx, Inc. – Pipeline Analysis
Ambrx, Inc. – Pipeline Products by Therapeutic Class
Ambrx, Inc. - Pipeline Products By Target
Ambrx, Inc. – Pipeline Products by Molecule Type
Ambrx, Inc. – Recent Pipeline Updates
Ambrx, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jun 19, 2007: Merck Serono And Ambrx To Collaborate On Development Of Next Generation Growth Hormone Products
Dec 18, 2007: Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration With Merck And Co. Inc.
Nov 13, 2008: Clinical Data Show Long-Acting Human Growth Hormone ARX201 Is Safe And Well Tolerated
Feb 12, 2007: Ambrx Initiates Phase I/II Clinical Trial Of Novel Human Growth Hormone Product Candidate
Financial Deals Landscape
Ambrx, Inc., Deals Summary
Ambrx, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Ambrx Secures $10 Million In Series D Financing
Ambrx Secures $55 Million In Series C Financing
Ambrx Secures $23.4 Million In Series B Financing
Partnerships
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ambrx
Fabrus Enters Into Research Agreement With Ambrx
Wyeth Pharmaceuticals Enters Into An Agreement With Ambrx
Merck Serono Expands An Agreement With Ambrx
Ambrx Enters Into Drug Discovery Collaboration With Merck
Ambrx Enters Into Agreement With Eli Lilly
Merck Serono Enters Into A Collaboration With Ambrx
Licensing Agreements
Ambrx Enters Into Licensing Agreement With Roche
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Ambrx, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Ambrx, Inc. – Pipeline by Stage of Development, H2 2011
Ambrx, Inc. – Monotherapy Products in Pipeline, H2 2011
Ambrx, Inc. - Phase II, H2 2011
Ambrx, Inc. - Pipeline By Therapeutic Class, H2 2011
Ambrx, Inc. - Pipeline By Target, H2 2011
Ambrx, Inc. – Pipeline By Molecule Type, H2 2011
Ambrx, Inc. – Recent Pipeline Updates, H2 2011
Ambrx, Inc., Deals Summary
Ambrx Secures $10 Million In Series D Financing
Ambrx Secures $55 Million In Series C Financing
Ambrx Secures $23.4 Million In Series B Financing
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ambrx
Fabrus Enters Into Research Agreement With Ambrx
Wyeth Pharmaceuticals Enters Into An Agreement With Ambrx
Merck Serono Expands An Agreement With Ambrx
Ambrx Enters Into Drug Discovery Collaboration With Merck
Ambrx Enters Into Agreement With Eli Lilly
Merck Serono Enters Into A Collaboration With Ambrx
Ambrx Enters Into Licensing Agreement With Roche
List of Figures
Ambrx, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Ambrx, Inc. – Pipeline by Stage of Development, H2 2011
Ambrx, Inc. – Monotherapy Products in Pipeline, H2 2011
Ambrx, Inc. – Pipeline By Molecule Type, H2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
